Subcutaneous Amivantamab for NSCLC Could Benefit Patients, Practices: Balazs Halmos, MD | AJMC
Subcutaneous Amivantamab for NSCLC Could Benefit Patients, Pr…
6 个月之前
ajmc.com
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management | OncLive
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCL…
1 个月前
onclive.com
Implications of the FDA Approval of Subcutaneous Amivantamab in EGFR-Mutated NSCLC | OncLive
Implications of the FDA Approval of Subcutaneous Amivantamab in E…
4 周前
onclive.com
Promising Efficacy Seen With Amivantamab Regimen in R/R Metastatic CRC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Promising Efficacy Seen With Amivantamab Regimen in R/R Met…
2 个月之前
targetedonc.com
FDA Approval of Subcutaneous Amivantamab Is Significant Step Forward in NSCLC: Martin Dietrich, MD, PhD | AJMC
FDA Approval of Subcutaneous Amivantamab Is Significant Step F…
4 个月之前
ajmc.com
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Targeted therapy in a shot: New approval for EGFR-mutated lung c…
3 个月之前
MSNDr. Kaique Filardi
Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial | OncLive
8:58
Subcutaneous Amivantamab vs Intravenous Amivantamab, Both i…
2024年6月25日
onclive.com
3:48
Amivantamab Accolades Add Up for NSCLC | AJMC
2024年9月27日
ajmc.com
ESMO 2025 Insights: Amivantamab in Recurrent/Metastatic HNSCC Af…
5 个月之前
vumedi.com
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mu…
2024年6月19日
onclive.com
2021 ASCO Review on EGFR Resistance Strategies in NSCLC: …
已浏览 275 次2021年11月21日
vumedi.com
Dr Joshua Sabari Discusses Amivantamab’s First-Line Approv…
2024年3月4日
ajmc.com
Novel Mechanisms Set FDA-Approved Amivantamab-Lazertini…
2024年8月30日
ajmc.com
3:38
Updates from PAPILLON: 1L Amivantamab Chemotherapy in A…
2023年11月14日
targetedonc.com
6:53
Amivantamab Lazertinib in EGFR-Mutated Advanced NSCLC: Result…
2023年11月14日
targetedonc.com
Adverse Event Management Strategies for Amivantamab-Base…
2025年2月19日
onclive.com
Amivantamab Toxicity Mitigation Strategies in the Treatment of EGF…
2025年4月7日
onclive.com
Dr Pietrantonio on Future Directions of Evaluating Amivantamab in CR…
2025年4月4日
onclive.com
Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon …
2023年9月12日
onclive.com
13:44
Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Tre…
2023年11月30日
onclive.com
Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemothe…
2023年10月21日
onclive.com
1:14
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertini…
2024年4月29日
onclive.com
Dr Arnold on the Evaluation of Chemo With Amivantamab or Cetu…
10 个月之前
onclive.com
0:07
📣 The U.S. Food and Drug Administration has approved a ne…
已浏览 259 次4 个月之前
FacebookGO2 for Lung Cancer
5:12
Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant …
已浏览 589 次1 个月前
YouTubeOncUpdates: Latest Oncology Insights
9:07
OS Benefit and Patient-Centered Delivery Advanced in EGFR-Positi…
已浏览 609 次1 个月前
YouTubeOncUpdates: Latest Oncology Insights
1:13
Dr Mehra on the FDA Breakthrough Therapy Designation for Amivanta…
已浏览 30 次2 周前
YouTubeOncLive
5:27
Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mut…
已浏览 26 次1 个月前
YouTubeOncUpdates: Latest Oncology Insights
1:16
奥希替尼后继有药，强生EGFR/cMET双抗临床数据乐观
已浏览 718 次2023年9月7日
bilibili药时代
3:01
About Advanced (Metastatic) Prostate Cancer
已浏览 7.3万 次2020年11月9日
YouTubeMacmillan Cancer Support
观看更多视频
静态缩略图占位符